Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Evaluation of the objective tumor response of the combination therapy with pimasertib plus SAR245409 and of pimasertib plus SAR245409 placebo in subjects with previously treated unresectable low-grade ovarian carcinoma according to Response Evaluation Criteria in Solid Tumors Version 1.1. (RECIST v1.1) as determined by the investigator.
Critère d'inclusion
- Unresectable Low Grade Ovarian Cancer